LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise. LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise.

X

Find the latest Drugs in Development and Pipeline Prospector News of Curia.

  • Webinars & Exhibitions

  • Beclomethasone Dipropionate

  • Ganaxolone

  • Tapentadol

  • Viloxazine Hydrochloride

PharmaCompass
Curia VB RM
Curia
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
26 Corporate Circle, Albany, New York 12203
Telephone
Telephone
+1 518.512.2000
Contact Info
Others

Contact email: customerservice@curiaglobal.com 

 

Sales Offices: 

ITALY

Rozzano - Quinto de’ Stampi

Via Volturno, 41/43

20089 - Rozzano (MI) - Italy

Tel: +39 02 822 72 1

 

SPAIN

Parque Tecnológico, Parcela 105

47151 Boecillo, Valladolid, Spain

Tel: +34 983 54 80 72

 

JAPAN

Level 28 Shinagawa Intercity Tower A

2-15-1 Konan Minato-ku

Tokyo 108-6028, Japan

Tel: +81 3 6717 2807 

 

CHINA

Shanggu Commercial Center A-601

Tian Ta Street, Nankai District

Tianjin 300381, China

Tel: +86 22 23412321

 

INDIA

713, Exim Link Building

Opp. Indira Container Yard

Mulund – Goregoan Link Road, Nahur (W)

Mumbai – 400078, India

Tel: 022 67250230-31 

 

API Manufacturing Sites

 

UNITED STATES

RENSSELAER

33 Riverside Avenue

Rensselaer, New York 12144 USA

 

ALBANY

21 Corporate Circle

Albany, New York 12203 USA

 

GRAFTON

870 Badger Circle

Grafton, Wisconsin 53024 USA

 

SPRINGFIELD

2460 West Bennett Street

Springfield, Missouri 65807 USA

 

FRANCE

BON ENCONTRE

Zone Industrielle de Laville

F-47240 - Bon-Encontre - France

 

TONNEINS

Avenue du Dr Nicole Bru

F-47400 - Tonneins - France

 

GERMANY

FRANKFURT

Industriepark Höchst

65926 - Frankfurt - Germany

 

ITALY

ROZZANO - Quinto de’ Stampi

Via Volturno, 41/43

20089 - Rozzano (MI) - Italy

ROZZANO - Valleambrosia

Via Monterosa, 114

20089 - Rozzano (MI) - Italy

ORIGGIO

Viale Europa, 5

21040 - Origgio (VA) - Italy

 

SPAIN

VALLADOLID

Parque Tecnológico, Parcela 105

47151 Boecillo, Valladolid, Spain 

 

INDIA

AURANGABAD

Curia India Pvt. Ltd.

G-1/1, 1/2, MIDC Area

Waluj, Aurangabad 431 136

(Maharashtra), India

 

AURANGABAD

Finkem Laboratories Pvt. Ltd.

G-39/5, MIDC Area

Waluj, Aurangabad 431 136

(Maharashtra), India

 

 

 

Details:

Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.


Lead Product(s): Murine Monoclonal Antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 12, 2022

Details:

IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.


Lead Product(s): Cannabidiol,Isoflurane

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: Incannex Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 02, 2022

Details:

Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.


Lead Product(s): Liafensine

Therapeutic Area: Psychiatry/Psychology Product Name: DB104

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Denovo Biopharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2022

Details:

As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.


Lead Product(s): srRNA Therapeutic

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Replicate Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 09, 2022

Details:

Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.


Lead Product(s): Clascoterone

Therapeutic Area: Dermatology Product Name: Winlevi

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Cassiopea

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 30, 2020

Details:

Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.


Lead Product(s): Bryostatin-1

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: BryoLogyx Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 13, 2020

Details:

Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.


Lead Product(s): ChAdOx1 nCoV-19

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Phase IIIProduct Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 03, 2020

Details:

Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.


Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Tryp Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 13, 2020

Details:

The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.


Lead Product(s): Merimepodib,Remdesivir

Therapeutic Area: Infections and Infectious Diseases Product Name: VX-497

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: BioSig Technologies

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 08, 2020

Details:

In return, under a supply agreement, BryoLogyx will supply Neurotrope with specified amounts of synthetic, Bryostatin-1 will be chemically synthesized by Curia in collaboration with BryoLogyx.


Lead Product(s): Bryostatin-1

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: BryoLogyx Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 11, 2020

Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY